Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...

Policy / Regulatory

China’s State Council Boosts Internet Medical Services Amid COVID-19

Fineline Cube Dec 13, 2022

The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...

Company Drug

Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202

Fineline Cube Dec 13, 2022

China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...

Company Drug

Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone

Fineline Cube Dec 13, 2022

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...

Company Drug

Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment

Fineline Cube Dec 13, 2022

China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...

Company Deals

Yantai Dongcheng to Acquire US Firm XingImaging for $30.2M

Fineline Cube Dec 13, 2022

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) is set to acquire a 100%...

Company Medical Device

Hotgen Biotech’s COVID-19 Antigen Home Test Approved in Russia

Fineline Cube Dec 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) announced receiving market approval in Russia for its...

Company Drug

Angel Pharmaceuticals Presents CPI-818 Data at ASH 2022 Annual Meeting

Fineline Cube Dec 13, 2022

China-based Angel Pharmaceuticals Ltd announced the latest results of the global Phase I/Ib clinical study...

Company R&D

ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform

Fineline Cube Dec 13, 2022

Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with...

Company Deals

Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 13, 2022

China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...

Company Drug

JW Therapeutics Presents Carteyva Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...

Company Deals

4B Technologies Raises RMB 100M in Pre-Series B Financing Round

Fineline Cube Dec 13, 2022

China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development,...

Company Deals

Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share

Fineline Cube Dec 13, 2022

China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong...

Company Policy / Regulatory

Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling

Fineline Cube Dec 13, 2022

Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the...

Company Drug

Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting

Fineline Cube Dec 13, 2022

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205)...

Company Deals

HitGen and Nitrase Therapeutics Enter Research Agreement

Fineline Cube Dec 12, 2022

China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc....

Company Deals R&D

Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research

Fineline Cube Dec 12, 2022

Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences...

Company Deals

Innoforce Partners with RNAimmune for mRNA Development and Production

Fineline Cube Dec 12, 2022

Hangzhou-based biopharma partner company Innoforce Pharmaceuticals Co., Ltd struck a partnership with RNAimmune, a spin-off...

Company Medical Device

NMPA Approves COVID-19 Antigen Detection Reagents from Four Companies

Fineline Cube Dec 12, 2022

The National Medical Products Administration (NMPA) announced the marketing approvals for COVID-19 antigen detection reagents...

Company Deals

Biozon Partners with Agilent Technologies to Boost ICP-MS in China Clinics

Fineline Cube Dec 12, 2022

Zhejiang-based third-party detection service company Biozon struck a partnership with US firm Agilent Technologies. The...

Posts pagination

1 … 641 642 643 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.